|

Trilaciclib Clinical Trials

7 actively recruiting trials across 1 location

Also known as: CDK 4/6 inhibitor, COSELA®, Cosela, G1T28, Trilaciclib combined with concurrent chemoradiotherapy +1 more

Pipeline

Phase 2: 6Phase 4: 1

Top Sponsors

  • wang shusen1
  • UNC Lineberger Comprehensive Cancer Center1
  • Shanghai Chest Hospital1
  • QIAO LI1
  • Pharmacosmos A/S1

Indications

  • Cancer7
  • Lung Cancer4
  • Breast Cancer2
  • Lung Cancer, Small Cell1
  • Myelosuppression1

Other6 trials

Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Phase 2
Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC
Phase 2
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
Phase 2
Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
Phase 2
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
Phase 2
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Phase 4

Lebanon, New Hampshire1 trial

Study of Trilaciclib and Lurbinectidin

Dartmouth Hitchcock Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.